Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongping Song

Showing results (221-230 of 252) with videos related to

Pageof 26
Sort By:
JAMA Oncology|November 7, 2024
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical TrialChunrui Li, Keshu Zhou, Yongxian Hu, et al.
Blood Advances|December 3, 2024
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemiaYing Wang, Lulu Lv, Yongping Song, et al.
Ebiomedicine|April 19, 2020
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Hang Su, Yongping Song, et al.
British Journal of Haematology|July 7, 2024
Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemiaFei Yang, Quan Ren, Yingling Zu, et al.
The Lancet. Haematology|January 8, 2019
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Hang Su, Yongping Song, et al.
Journal of Hematology & Oncology|August 18, 2022
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Hematology & Oncology|February 21, 2023
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Cancer Letters|September 27, 2024
Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 updateYu Wang, Ying-Jun Chang, Jing Chen, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
Journal of Hematology & Oncology|November 1, 2022
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Pageof 26

Showing results (221-230 of 252) with videos related to

Sort By:
Pageof 26
JAMA Oncology|November 7, 2024
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical TrialChunrui Li, Keshu Zhou, Yongxian Hu, et al.
Blood Advances|December 3, 2024
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemiaYing Wang, Lulu Lv, Yongping Song, et al.
Ebiomedicine|April 19, 2020
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Hang Su, Yongping Song, et al.
British Journal of Haematology|July 7, 2024
Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemiaFei Yang, Quan Ren, Yingling Zu, et al.
The Lancet. Haematology|January 8, 2019
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Hang Su, Yongping Song, et al.
Journal of Hematology & Oncology|August 18, 2022
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Hematology & Oncology|February 21, 2023
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Cancer Letters|September 27, 2024
Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 updateYu Wang, Ying-Jun Chang, Jing Chen, et al.
Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.
Journal of Hematology & Oncology|November 1, 2022
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Pageof 26